跳至主要内容

Medicilon appeared at the 25th SAPA-NE Annual Conference

 On June 3, 2023, the 25th annual conference of SAPA-NE (Sino-American Pharmaceutical Professionals Association–New England/Boston) was successfully held in Boston, MA. Dr. Chunlin Chen, CEO of Medicilon, Dr. Zhenrong Guo, Executive Vice President of Pharmaceutical Research, and the Medicilon US team attended the annual conference and had pleasant and in-depth exchanges with many guests and experts during the conference. With professional quality, confident demeanor, and exhibitions as a platform, Medicilon fully demonstrates and delivers the values of "focus on innovation, win-win collaboration, client first, and loving and dedication". During the conference, the Medicilon team conducted in-depth exchanges with a lot of pharmaceutical colleagues, and discussed about the industry situation and market prospects.

From left to right Cindy Chen, Dr. Jun Li, Dr. Chunlin Chen, Dr. Zhenrong Guo, Dr. Yan Zhou.webp

From left to right: Cindy Chen, Dr. Jun Li, Dr. Chunlin Chen, Dr. Zhenrong Guo, Dr. Yan Zhou

Dr. Chunlin Chen of Medicilon was invited to give a wonderful speech on "Medicilon Strategy & 20 Years Experience for Dual Filing of IND to US FDA & China NMPA along with IPO at STAR Market". Since its establishment in 2004, Medicilon has provided drug R&D services to more than 2,000 clients around the world during the 20-year milestone. More than 330 new drug and generic drug projects that have participated in the research and development have obtained IND approval. In the past 20 years, Medicilon has grown together with the partners around the world.

Dr. Chen shared an in-depth analysis and case study.webp

Based on Medicilon's nearly 20 years of experience in IND filing, Dr. Chen shared an in-depth analysis and case study.

The 25th SAPA-NE Annual Conference attracted many professionals from the biotechnology and pharmaceutical industries to attend. Through intensive exchanges and discussion, the participants had in-depth discussion with industry organizations on how to meet the transformation in this challenging situation. Participants exchanged views on new trends in the industry in terms of new drug R&D, AI pharmaceuticals, technological innovation, pharmaceutical investment, and regulatory oversight.

The audience listened to Dr. Chen's speech.webp

The audience listened to Dr. Chen's speech.

As the Diamond Sponsor of the 25th SAPA-NE Annual Conference, the dinner event was exclusively sponsored by Medicilon. The well-arranged drinks and snacks allowed participants to enjoy the opportunity to communicate with different professionals after a busy meeting. The buffet dinner drew a perfect end to the busy day of business negotiation.

Medicilon, as a professional biopharmaceutical preclinical R&D service CRO, provides global pharmaceutical companies and research institutions with a full range of one-stop new drug R&D services that meet both China and US filing standards. Through this exhibition, the influence of the Medicilon has been further enhanced internationally. In order to realize the vision of "providing a full range of preclinical research services for global pharmaceutical companies, research institutions and all scientific researchers, and promoting the process of new drug research", Medicilon will continue to deepen the overseas high-end market, explore the European and American markets, and accelerate the pace of internationalization.

标签：

评论

发表评论

此博客中的热门博文

The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study

  Chuansha, Shanghai, Nov. 8th, 2019 — Medicilon held the launch meeting with Hangzhou DAC Biotech Co., Ltd to initiate the   preclinical study   of the antibody-drug-conjugate (ADC)  DXC005, including the   pharmacology study ,   DMPK study   and the   safety evaluation . Medicilon has previously completed integrated  preclinical research  on ADC drugs cooperating with DAC Biotech and other companies. Two of them has been approved by NMPA and entered Phase I clinical trials. About Hangzhou DAC Biotech Co., Ltd Hangzhou DAC Biotech, Co., Ltd was officially registered in HEDA Area, Hangzhou City, Zhejiang Province, China around the end of Year 2012, and is located nearby the bank of beautiful Qiantang River. The company focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drug, both of which are banded together with smart linkers. About Antibody-Drug-Conjugate (ADC) ADCs ...
发表评论
阅读全文

Medicilon assisted Hangzhou DAC Biotech in approval of clinical study of ADC drug DAC-002

  On July 20, 2020, DAC Biotech’s new   ADC drug development , TROP2-ADC—DAC-002 was approved of clinical study by NMPA. for the indication of solid malignant tumor. Medicilon completed   preclinical pharmacokinetic  and toxicological studies in this project, accelerating the development process. DAC-002 is an ADC anti-Trop2 monoclonal antibody conjugated by an intelligent ligand against Tubulysin B analogue. It is used to treat Trop2 triple negative breast cancer, small cell lung cancer, non-small cell lung cancer and pancreatic cancer.Trop2 can promote the proliferation, invasion, metastasis and diffusion of tumor cells, and its high expression is closely related to the shortening of survival time and poor prognosis of tumor patients. Therefore, it is of great significance to study anti-tumor drugs targeted by Trop2. Reference: Medicilon Assists - The first China-made targeting folic acid receptor FRα ADC injection BAT8006 was approved for clinical use Medicilon As...
发表评论
阅读全文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...
发表评论
阅读全文